Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|October 12, 2012
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancerM Provencio, C Camps, M Cobo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM groupM Martin, A Villar, A Sole-Calvo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.European Journal of Cancer (Oxford, England : 1990)|May 13, 2015
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive TumoursJ Sastre, B Massuti, G Pulido, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerF Cardenal, M P López-Cabrerizo, A Antón, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patientsR de las Peñas, M Sanchez-Ronco, V Alberola, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2014
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyE Van Cutsem, C Boni, J Tabernero, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trialE Felip, S Popat, U Dafni, et al.Pageof 4